Fig. 6
Therapeutic efficacy of CKI on the patient-derived xenograft model of acute myeloid leukaemia. a The schematic diagram for the AML PDX model. b Analysis of bone marrow smear. At day 20, the bone marrow smear was stained and leukaemia cells were observed. Magnification fold: × 100 under an oil immersion lens. c The changes in body weight. d The survival analysis. e The remission state of bone marrow in the CKI group. f The immunophenotype of leukaemia cells in peripheral blood by flow cytometry analysis. g Statistics for the ratio of leukaemia cells. h The tissue weight index. i Testing the T-AOC vitality, GSH content, H2O2 concentration and CAT activity in plasma from B-NSG mice. j Detection of Prdx3, Prdx2, and Trx1 expression by IHC in the PDX model. k The model for the anti-leukaemic effects of CKI